Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Carboplatin + Etoposide + RRx-001 |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Carboplatin | Paraplatin | CBDCA | Chemotherapy - Platinum 7 | Paraplatin (carboplatin) is a second-generation platinum compound and is activated intracellularly to form reactive platinum complexes that cross link DNA with DNA and with proteins. This induces apoptosis and inhibits cell growth (NCI Drug Dictionary). |
Etoposide | Vepesid | EPEG|Eposin|VP-16|VP-16-213 | TOPO2 inhibitor 5 | Vepesid (etoposide) binds to and inhibits DNA topoisomerase II, resulting in accumulated DNA damage, inhibition of replication, and cell death (NCI Drug Dictionary). |
RRx-001 | RRx-001 is a nitric oxide donor that is activated by hypoxia, leading to increased oxygen level in tumor and sensitizes tumor to radiotherapy (PMID: 26164533, PMID: 32169409). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05566041 | Phase III | Cisplatin + Etoposide Carboplatin + Etoposide + RRx-001 Cisplatin + Etoposide + RRx-001 Carboplatin + Etoposide | A Phase 3, Controlled, Open-label, Global Randomized Study of RRx-001 With a Platinum Doublet or a Platinum Doublet in Small Cell Lung Cancer (REPLATINUM) | Active, not recruiting | USA | 0 |